WASHINGTON, DC and ATLANTA - LexisNexis® Risk Solutions today announced the company has been certified by the U.S. government-approved Trust Framework Provider, SAFE-BioPharma Association. This certification means that identity credentials can be trusted and used at known levels of assurance by U.S. federal agencies, such as the Department of Veterans Affairs, National Institutes of Health and Food and Drug Administration. On Friday, the White House issued an Executive Order, directing the government to lead by example in securing transactions and sensitive data.
“In today’s environment where we must be vigilant in safeguarding information, we support the Executive Order’s charge ‘to ensure that all agencies making personal data accessible to citizens through digital applications require the use of multiple factors of authentication and an effective identity proofing process,’” said Kim Little Sutherland, Senior Director, Identity Management, LexisNexis. “This accreditation offers our customers further peace of mind that LexisNexis manages sensitive information with the same level of care and diligence that they would expect for an agency of the federal government. It also demonstrates LexisNexis capabilities in identity management and multi-factor authentication to enable secure consumer relationships with their health care organizations and government agencies.”
As an Identity Proofing Component Member, LexisNexis has satisfied all requirements for Identity Proofing at the National Institute of Standards and Technology (NIST) Levels 1, 2, and 3 under the Federal Identity, Credential & Access Management (FICAM) Trust Framework Provider 1.0 program.
The FICAM program was set up in response to the government-wide need for a comprehensive, standardized identity management and cybersecurity policy framework, as called for by multiple agencies and most notably in the White House’s Open Government Initiative. As a FICAM-approved entity, the SAFE-BioPharma Association provides policy and practice oversight for full-service Credential Service Providers (CSP), Identity Proofing (IdP) authorization protocol component members, such as LexisNexis, and Credential Provider (CCP) component members. LexisNexis has been authorized up to the third Level of Assurance, which adds cryptographic strength mechanisms and authentication procedures to guard the authentication token against compromise.
The scope of the accreditation covers the LexisNexis Instant Authenticate and Multi-Factor Authentication solutions, which ensure issuing authorization and access privileges for authorized recipients and offer scalable authentication procedures in accordance with NIST Levels of Assurance. Also included in this accreditation are the LexisNexis InstantID® and InstantID® Q&A solutions, identity verification and identity fraud prevention systems that offer scalable security comparable to the difference between NIST levels 1 and 3.
About LexisNexis Risk Solutions
At LexisNexis Risk Solutions, we believe in the power of data and advanced analytics for better risk management. With over 40 years of expertise, we are the trusted data analytics provider for organizations seeking actionable insights to manage risks and improve results while upholding the highest standards for security and privacy. Headquartered in metro Atlanta USA, LexisNexis Risk Solutions serves customers in more than 100 countries and is part of RELX Group, a global provider of information and analytics for professional and business customers across industries. For more information, please visit www.risk.lexisnexis.com.
SAFE-BioPharma manages the SAFE-BioPharma global digital identity and digital signatures standard, developed for and used extensively throughout the biopharmaceutical industry. LOA 2 satisfies identity-proofing and credential issuing practices acceptable for access to systems where risk of identity fraud is minimized, including patient access to read-only medical records. LOA 3 identity credentials are required to authenticate most transactions in regulated industries such as pharmaceuticals and healthcare. http://www.safe-biopharma.org